SYGNIS Announces Double Switch Technology Patent Deal with SYSTASY

News   May 13, 2014

 
SYGNIS Announces Double Switch Technology Patent Deal with SYSTASY
 
 
 

RELATED ARTICLES

Sheep Toxin Could Cause MS

News

Exposure to a toxin primarily found in sheep could be linked to the development of multiple sclerosis (MS) in humans, new research suggests.

READ MORE

Compound Offers Pain-relief of Opioids Without Addictive Properties

News

Researchers have engineered a new compound that animal tests suggest could offer the pain-relieving properties of opioids such as morphine and oxycodone without the risk of addiction.

READ MORE

Compound Selectively Kills Liver Cancer Stem Cells

News

Acyclic retinoid, an artificial compound derived from vitamin A, has been found to prevent the recurrence of hepatocellular carcinoma (HCC), the most common form of liver cancer.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE